Stockreport

Nuvation Bio Surges On Ibtrozi Momentum And B. Riley Buy Rating [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF NUVB surged nearly 48% after B. Riley Securities initiated coverage with a Buy rating and $12 price target, citing robust Ibtrozi launch momentum. To meet 2026 revenu [Read more]